Research graph
References from Safety landscape of bispecific antibody therapy in non-Hodgkin lymphoma: a meta-analysis. Local targets link to admitted publications; unresolved targets remain external evidence.
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
10.1056/nejmoa011795 · 2002 · External reference
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era
10.1200/jco.2010.28.1618 · 2010 · External reference
Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities
10.1182/blood.2021011994 · 2023 · External reference
Bispecific antibodies
10.1016/j.drudis.2015.02.008 · 2015 · External reference
Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma
10.7573/dic.2021-2-4 · 2021 · External reference
Current landscape and future directions of bispecific antibodies in cancer immunotherapy
10.3389/fimmu.2022.1035276 · 2022 · External reference
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
10.1016/s1470-2045(22)00335-7 · 2022 · External reference
Glofitamab for relapsed or refractory diffuse large B-cell lymphoma
10.1056/nejmoa2206913 · 2022 · External reference
Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial
10.1200/jco.22.01725 · 2023 · External reference
ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
10.1016/j.bbmt.2018.12.758 · 2019 · External reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
2021 · External reference
Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial
10.1016/s2352-3026(22)00072-2 · 2022 · External reference
Glofitamab (Glofit) in combination with polatuzumab vedotin (Pola): phase Ib/II preliminary data support manageable safety and encouraging efficacy in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
10.1182/blood-2021-148359 · 2021 · External reference
CD19 4-1BBL (RO7227166) a novel costimulatory bispecific antibody can be safely combined with the T-cell-engaging bispecific antibody glofitamab in relapsed or refractory B-cell non-Hodgkin lymphoma
10.1182/blood-2022-157011 · 2022 · External reference
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial
10.1038/s41375-024-02410-8 · 2024 · External reference
CAR T-cell vs bispecificantibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis
10.1182/blood.2023023419 · 2024 · External reference
Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
2022 · External reference
Cytopenia after CAR-T cell therapy: analysis of 63 patients with relapsed and refractory B-cell non-Hodgkin lymphoma
10.3892/ol.2023.13924 · 2023 · External reference
IgG replacement in multiple myeloma
10.1038/s41408-024-01107-6 · 2024 · External reference
IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence
10.1182/bloodadvances.2024013073 · 2024 · External reference
Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
10.1182/bloodadvances.2022009435 · 2023 · External reference
Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma
10.1002/cncr.34756 · 2023 · External reference
Dose-escalation part of phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma
10.1093/jjco/hyad082 · 2023 · External reference
Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study
10.1200/jco.2014.59.1586 · 2016 · External reference
Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
10.1056/nejmoa1707447 · 2017 · External reference
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
10.1016/s1470-2045(21)00591-x · 2022 · External reference
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
10.1038/s41591-021-01622-0 · 2022 · External reference
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
10.1182/blood-2015-06-651380 · 2016 · External reference
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
10.1182/bloodadvances.2022009260 · 2023 · External reference
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
10.1016/s0140-6736(21)00889-8 · 2021 · External reference
Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study
10.1200/jco.21.00931 · 2022 · External reference
Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL
10.1080/10428194.2022.2064981 · 2022 · External reference
